The ESADE Alumni Innovation Club and Alumni Entrepreneurship host the talk ''Five disruptive forms of healthcare innovation and enterprise'' on 24 May 2016. Dr. Raúl Insa, SOM Biotech CEO, will be one of the speakers. Five entrepreneurs and managers in the healthcare industry use ''disruptive innovation'' to differentiate their products and services in the market and thus achieve their goals…

SOM Biotech will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an…

TTR Amyloidosis Phase IIa results will be presented by Dr. Josep Gàmez at AAN 2016 Annual Meeting to be held in Vancouver (Canada) from 15th to 21th of April. This Clinical Trial has been performed by SOM Biotech and VHIR (Vall d'Hebron Hospital Institute of Research). Further information about the meeting at AAN 2016 Annual…

The article ‘Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity’ has recently been published on Nature Communications. SOM0226 (tolcapone) is a strong candidate for therapeutic intervention in the TTR Amyloidosis variants, including those affecting the central nervous system, for which no small-molecule therapy exists. Several institutions have taken part on this research as…

SOM Biotech is a repositioning clinical-stage biopharmaceutical company focused on Rare Diseases. Why repositioning and orphan? See this article to get the answer. Chinese Version English Version 

SOM Biotech has launched a crowdfunding campaign